356 related articles for article (PubMed ID: 17470523)
1. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
2. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
4. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
7. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
8. Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms In Vitro.
Cai J; Dai DP; Geng PW; Wang SH; Wang H; Zhan YY; Huang XX; Hu GX; Cai JP
Basic Clin Pharmacol Toxicol; 2016 Mar; 118(3):190-9. PubMed ID: 26310775
[TBL] [Abstract][Full Text] [Related]
9. In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.
Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
Drug Metab Pharmacokinet; 2014; 29(1):52-60. PubMed ID: 23857029
[TBL] [Abstract][Full Text] [Related]
10. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
11. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.
Volotinen M; Turpeinen M; Tolonen A; Uusitalo J; Mäenpää J; Pelkonen O
Drug Metab Dispos; 2007 Jul; 35(7):1135-41. PubMed ID: 17431033
[TBL] [Abstract][Full Text] [Related]
12. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
13. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine.
Ring BJ; Eckstein JA; Gillespie JS; Binkley SN; VandenBranden M; Wrighton SA
J Pharmacol Exp Ther; 2001 Jun; 297(3):1044-50. PubMed ID: 11356927
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
17. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
Dalén P; Dahl M; Andersson K; Bertilsson L
Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.
Glass SM; Martell CM; Oswalt AK; Osorio-Vasquez V; Cho C; Hicks MJ; Mills JM; Fujiwara R; Glista MJ; Kamath SS; Furge LL
Drug Metab Dispos; 2018 Aug; 46(8):1106-1117. PubMed ID: 29784728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]